IAN E KROP

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi request reprint Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial
    IAN E KROP
    Dana Farber Cancer Institute, Harvard University School of Medicine, Boston, MA, USA Electronic address
    Lancet Oncol 15:689-99. 2014
  2. pmc Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer
    L M Flores
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Br J Cancer 102:1495-502. 2010
  3. ncbi request reprint A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine
    IAN E KROP
    Dana Farber Cancer Institute, 450 Brookline Ave, Boston MA 02215, USA
    J Clin Oncol 30:3234-41. 2012
  4. ncbi request reprint Chemokine signaling in gliomas: prognostic factor, therapeutic target or both?
    IAN E KROP
    Department of Medical Oncology, Dana Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Biol Ther 5:1039-41. 2006
  5. ncbi request reprint Neoadjuvant bevacizumab: surgical complications of mastectomy with and without reconstruction
    Kari Joanne Kansal
    Brigham and Women s Hopspital, Boston, MA, USA
    Breast Cancer Res Treat 141:255-9. 2013
  6. ncbi request reprint Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer
    IAN E KROP
    Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    J Clin Oncol 28:2698-704. 2010
  7. pmc Disruption of laminin-integrin-CD151-focal adhesion kinase axis sensitizes breast cancer cells to ErbB2 antagonists
    Xiuwei H Yang
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute and Harvard Medical School, University of Massachusetts, Boston, Massachusetts, USA
    Cancer Res 70:2256-63. 2010
  8. pmc A phase II study of sagopilone (ZK 219477; ZK-EPO) in patients with breast cancer and brain metastases
    Rachel A Freedman
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Harvard Medical School, Boston, MA 02115, USA
    Clin Breast Cancer 11:376-83. 2011
  9. pmc Prospective clinical experience with research biopsies in breast cancer patients
    Ines Vaz-Luis
    Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA
    Breast Cancer Res Treat 142:203-9. 2013
  10. pmc Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study
    Ines Vaz-Luis
    Department of Medical Oncology, Dana Farber Cancer Institute, Breast Oncology Center, Boston, MA 02215, USA
    Clin Breast Cancer 13:254-63. 2013

Collaborators

Detail Information

Publications15

  1. ncbi request reprint Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial
    IAN E KROP
    Dana Farber Cancer Institute, Harvard University School of Medicine, Boston, MA, USA Electronic address
    Lancet Oncol 15:689-99. 2014
    ..We aimed to compare trastuzumab emtansine, an antibody-drug conjugate comprising the cytotoxic agent DM1 linked to trastuzumab, with treatment of physician's choice in this population of patients...
  2. pmc Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer
    L M Flores
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Br J Cancer 102:1495-502. 2010
    ..Circulating tumour cells (CTCs) offer a non-invasive approach to obtain and characterise metastatic tumour cells, but their usefulness has been limited by low CTC yields from conventional isolation methods...
  3. ncbi request reprint A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine
    IAN E KROP
    Dana Farber Cancer Institute, 450 Brookline Ave, Boston MA 02215, USA
    J Clin Oncol 30:3234-41. 2012
    ....
  4. ncbi request reprint Chemokine signaling in gliomas: prognostic factor, therapeutic target or both?
    IAN E KROP
    Department of Medical Oncology, Dana Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Biol Ther 5:1039-41. 2006
  5. ncbi request reprint Neoadjuvant bevacizumab: surgical complications of mastectomy with and without reconstruction
    Kari Joanne Kansal
    Brigham and Women s Hopspital, Boston, MA, USA
    Breast Cancer Res Treat 141:255-9. 2013
    ..As larger data sets become available with the use of neoadjuvant bevacizumab with mastectomy, further refinement may be necessary. ..
  6. ncbi request reprint Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer
    IAN E KROP
    Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    J Clin Oncol 28:2698-704. 2010
    ..This first-in-human study of T-DM1 evaluated safety, pharmacokinetics, and preliminary activity of T-DM1 in patients with advanced HER2-positive breast cancer...
  7. pmc Disruption of laminin-integrin-CD151-focal adhesion kinase axis sensitizes breast cancer cells to ErbB2 antagonists
    Xiuwei H Yang
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute and Harvard Medical School, University of Massachusetts, Boston, Massachusetts, USA
    Cancer Res 70:2256-63. 2010
    ..These new insights should be useful when devising strategies for overcoming drug resistance in ErbB2+ cancers...
  8. pmc A phase II study of sagopilone (ZK 219477; ZK-EPO) in patients with breast cancer and brain metastases
    Rachel A Freedman
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Harvard Medical School, Boston, MA 02115, USA
    Clin Breast Cancer 11:376-83. 2011
    ..We observed modest activity with a central nervous system objective response rate of 13.3%; however, median PFS was disappointing. Further studies should focus on other agents to treat this challenging clinical problem...
  9. pmc Prospective clinical experience with research biopsies in breast cancer patients
    Ines Vaz-Luis
    Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA
    Breast Cancer Res Treat 142:203-9. 2013
    ..This supports continued efforts to study tissue samples at multiple points in a patient's disease course...
  10. pmc Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study
    Ines Vaz-Luis
    Department of Medical Oncology, Dana Farber Cancer Institute, Breast Oncology Center, Boston, MA 02215, USA
    Clin Breast Cancer 13:254-63. 2013
    ..In this retrospective study, we investigated the clinicopathological features associated with prolonged first-line trastuzumab-based treatment duration...
  11. pmc A phase II study of preoperative capecitabine in women with operable hormone receptor positive breast cancer
    Sara M Tolaney
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts
    Cancer Med 3:293-9. 2014
    ..Preoperative capecitabine is a well-tolerated regimen, but appears not lead to pCR when used as monotherapy in HR+ breast cancer...
  12. doi request reprint Prevalence of germline TP53 mutations in HER2+ breast cancer patients
    Michelle G Rath
    Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA
    Breast Cancer Res Treat 139:193-8. 2013
    ..Given the potential clinical impact, consideration of germline TP53 testing should be given to young women with HER2+ breast cancer, especially if family cancer history is notable...
  13. doi request reprint Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers
    Marta Guix
    Department of Medicine, Vanderbilt Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232 6307, USA
    J Clin Oncol 26:897-906. 2008
    ....
  14. doi request reprint Advances in targeting SRC in the treatment of breast cancer and other solid malignancies
    Erica L Mayer
    Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 16:3526-32. 2010
    ..Future trials will continue to explore the contribution of Src inhibition with both chemotherapy and targeted agents...
  15. ncbi request reprint Mechanisms of trastuzumab resistance in breast cancer
    Sara M Tolaney
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Anticancer Agents Med Chem 9:348-55. 2009
    ..In this review, we discuss the mechanisms of antitumor activity of trastuzumab, potential mechanisms contributing to its resistance, and novel therapeutic agents that may provide a means to overcome trastuzumab resistance...